Samsung BioLogics Archives | Be Korea-savvy
Samsung Biologics Inks Manufacturing Deal with GSK

Samsung Biologics Inks Manufacturing Deal with GSK

SEOUL, May 22 (Korea Bizwire) — South Korea’s top pharmaceutical firm, Samsung Biologics Co., said Friday it has signed a tieup deal with multinational drug maker GlaxoSmithKline Plc. (GSK) to manufacture a GSK biosimilar product. Under the contract manufacturing organization (CMO) agreement, Samsung Biologics will commercially produce CSK’s lupus treatment, Benlysta, starting in 2022. The [...]

Samsung BioLogics Inks Manufacturing Deal for Coronavirus Treatment

Samsung BioLogics Inks Manufacturing Deal for Coronavirus Treatment

SEOUL, April 10 (Korea Bizwire) — Samsung BioLogics, a biopharmaceutical unit of South Korea’s Samsung Group, said Friday that it has clinched a US$362 million deal to manufacture a candidate treatment for the novel coronavirus. Under the deal, Samsung BioLogics will start full-scale production of U.S. drug firm Vir Biotechnology’s candidate COVID-19 treatment that is [...]

Samsung Electronics President Grilled About Accounting Scandal at Biotech Affiliates

Samsung Electronics President Grilled About Accounting Scandal at Biotech Affiliates

SEOUL, Jun. 11 (Korea Bizwire) — Chung Hyun-ho, president of Samsung Electronics, was questioned by prosecutors on Tuesday about his suspected involvement in alleged accounting fraud at the company’s biotech affiliates. The 59-year-old Chung, known as one of the closest aides to Samsung Electronics Vice Chairman Lee Jae-yong, arrived at the Seoul Central District Prosecutors [...]

Retail Investors Own Over 3 tln Won of Suspended Samsung Biologics

Retail Investors Own Over 3 tln Won of Suspended Samsung Biologics

SEOUL, Nov. 19 (Korea Bizwire) – Retail investors are estimated to hold more than 3 trillion won worth of Samsung BioLogics Co. shares, whose trading was suspended last week over window-dressing, a corporate researcher said Monday. As of last Wednesday, individual investors owned an estimated 9.6 million shares of Samsung BioLogics, or 14.53 percent, according [...]

Samsung BioLogics Expresses Concerns over FSS’s Leak of Sensitive Information

Samsung BioLogics Expresses Concerns over FSS’s Leak of Sensitive Information

SEOUL, May 8 (Korea Bizwire) — South Korea’s major biopharmaceutical firm Samsung BioLogics Co., which has been embroiled in an alleged violation of accounting rules, on Tuesday expressed concern over the financial watchdog’s disclosure of sensitive information. “We express deep concern and regret over the situation where sensitive information surrounding the case, which is under [...]

Samsung Biologics Wins Manufacturing Approval from Europe

Samsung Biologics Wins Manufacturing Approval from Europe

SEOUL, Dec. 13 (Korea Bizwire) — South Korean biopharmaceutical firm Samsung Biologics Co. said Wednesday it has won approval from European health authorities to manufacture drugs at its plant in Europe. The European Medicines Agency (EMA) accepted Samsung Biologics’ manufacturing application to make 152,000 liters of biosimilars at the plant, officials said. The approval comes [...]

Private-Public Sector Cooperation Crucial for Songdo Biopharmaceuticals Hub

Private-Public Sector Cooperation Crucial for Songdo Biopharmaceuticals Hub

SEOUL, Dec. 1 (Korea Bizwire) – To maintain its status as the world’s largest biopharmaceuticals manufacturing city, voices in Songdo are calling for greater cooperation between the private and public sectors.  Leading biopharmaceuticals firms, among them Samsung Biologics and Celltrion, have made large investments in Songdo to build up the city’s manufacturing capabilities. By next [...]

Samsung Bioepis Wins Approval to Sell Biosimilar in South Korea

Samsung Bioepis Wins Approval to Sell Biosimilar in South Korea

SEOUL, Sept. 20 (Korea Bizwire) – Samsung Biologics Co. said Wednesday its affiliate Samsung Bioepis Co. won a nod from South Korea’s drug agency to sell its biosimilar dubbed SB5. Through the approval granted by the Ministry of Food and Drug Safety, Samsung Biologics said in a regulatory filing that the biosimilar is ready for sale in the country. The SB5 is a biosimilar of Humira released by U.S.-based AbbVie Inc., used for the treatment of various diseases including Crohn’s [...]

Samsung BioLogics Tops Swiss Drug Giant Lonza in Market Cap

Samsung BioLogics Tops Swiss Drug Giant Lonza in Market Cap

SEOUL, Sept. 20 (Korea Bizwire) — South Korean biopharmaceutical maker Samsung BioLogics Co. has overhauled Swiss drug behemoth Lonza in terms of market value though its sales remain dwarfed by the latter’s top line, industry sources said Wednesday. The market capitalization of Samsung BioLogics, a unit of South Korea’s top conglomerate Samsung Group, came to [...]

Samsung BioLogics Suffers Operating Loss During Second Quarter

Samsung BioLogics Suffers Operating Loss During Second Quarter

SEOUL, July 24 (Korea Bizwire) – Samsung BioLogics, a biopharmaceutical unit of South Korea’s top conglomerate Samsung Group, suffered a loss in the second quarter despite a rise in sales, the company said Monday. Sales jumped 33 percent on-year to 63.2 billion won (US$57 million) during the April-June period, the company said in a regulatory [...]